In order to comply with TRIPS obligations, Bangladesh must provide full patent protection for pharmaceutical products. While lack of awareness and the absence of proper administrative and legal framework have been issues in some cases. The regulatory bodies in Bangladesh have to be prepared to cope with post TRIPS challenges from 1 January 2016. This paper examines the impact of trips on our pharmaceutical industry, as well as our preparation to deal with post TRIPS challenges and is intended to enrich the readers, industry’s owners, policy makers, employees of the sector about its current developments.
Bangladesh, compulsory license, generic, Patent, pharmaceutical, TRIPS